FDA 510(k) AVERAGE REVIEW TIME DROPS TO 114 DAYS FOR FIRST HALF OF FISCAL 1996; ODE'S ALPERT BELIEVES 510(k) "SUPPLEMENTS" FOR DEVICE CHANGES WORTH EXPLORING
This article was originally published in The Gray Sheet
Executive Summary
FDA's 510(k) review performance to date in fiscal year 1996 (ending Sept. 30) puts the agency on track to best its review time projections for the year, as well as FY 1997 projections based on the receipt of $24.5 mil. in user fees.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.